Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02866006
Recruitment Status : Recruiting
First Posted : August 15, 2016
Last Update Posted : July 18, 2018
Sponsor:
Information provided by (Responsible Party):
Cellid Co., Ltd.

Brief Summary:
BVAC-C is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell. This study is Open-label, dose-escalation, multiple dosing study to evaluate the safety, tolerability, immune response and pre efficacy of BVAC-C in patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer after failure to standard care. 9~18 patients will be enrolled

Condition or disease Intervention/treatment Phase
Uterine Cervical Neoplasms Drug: BVAC-C Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care
Study Start Date : October 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: BVAC-C
BVAC-C IV injection at 0, 4, 8th weeks.
Drug: BVAC-C
BVAC-C IV injection at 0, 4, 8th weeks.




Primary Outcome Measures :
  1. Evaluate DLT with Clinical laboratory tests [Safety] [ Time Frame: 12th week from first injection (End of trial) ]
    Lymphocyte subset, Serum cytokine, NKT/NK cell assay, CD4/CD8 assay

  2. Incidence of Serious Adverse Events assessed with CTCAE [Safety] [ Time Frame: 12th week from first injection (End of trial) ]

Secondary Outcome Measures :
  1. Clinical laboratory tests [ Time Frame: Screening visit and every 2 weeks from first injection (up to 12th week) ]
    Blood chemistry, Serology

  2. 12-lead ECG [ Time Frame: Screening visit and Termination visit (12th week from first injection) ]
  3. Vital signs [ Time Frame: Every 2 weeks from first injection (up to 12th week) ]
    Blood pressure, Pulse rate, Respiratory rate, Tympanic temperature

  4. Physical examination [ Time Frame: Screening, 6th week from first injection, 10th week from first injection and Termination visit (12th week from first injection) ]
    Body weight



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer
  • Patients has received 1 or more platinum based doublet chemotherapy as prior therapy for progressive or recurrent tumor lesion (prior therapy does not include platinum chemotherapy given with radiation therapy for 1st line treatment before progression or recurrence)
  • Patients with at least 1 measurable lesion according to RECIST
  • Female patients between ages of 20 to 70
  • Patients with ECOG performance status between 0 to 2
  • Patients meets the blood test standards in the screening test

    • ANC≥1500/μL
    • LLN ≤ALC ≤ULN
    • Platelets≥100,000/μL
    • Hemoglobin> 9g/dL
  • Patients meets the blood chemistry test standards in the screening test

    • Serum creatinine ≤ 2.0 mg/dL
    • Calculated creatinine clearance ≥ 50 mL/min
    • Serum bilirubin ≤1.5 x ULN
    • ALT and AST ≤2.5 × ULN (≤ 5 x ULN in patients with liver metastases)
  • Patients who has agreed to a medically accepted contraceptive in this clinical trial
  • Patients at least three months or more of survival can be expected
  • Patients decided to participate in this clinical trial and signed written informed consent

Exclusion Criteria:

  • Patients histopathology is a neuroendocrine or small cell carcinoma
  • Patients with a history of brain metastasis or signs of brain metastasis
  • Patients tested positive in serological tests for hepatitis C virus or hepatitis B virus surface antigen, (HBsAg) or human immunodeficiency virus (HIV)
  • Patients with a history of HIV infection
  • Patients showing abnormal electrocardiogram , including arrhythmia
  • Patients have been administered the drug for other clinical trials within 4weeks before the screening visit
  • Patients have been administered any vaccines within 4weeks before the screening visit (eg. hepatitis A, hepatitis B, influenza, Td, etc. )
  • Patients have been administered the blood products within 3 months before the screening visit
  • Patients have received chemotherapy or radiation therapy within 4weeks before the 1st administration of investigational drug (BVAC-C)
  • Patients treated with immunosuppressant or immunomodulatory agents within 6 months before the screening visit
  • Patients who have participated in the clinical trial of a therapeutic vaccine or immune therapy within 1 year before the screening visit
  • Patients with a history of serious allergic disease or serious side effects of the drug
  • Patients who is pregnant or breast-feeding
  • Patients researchers has determined that participation in the clinical trial is inappropriate
  • Patients suspected to have other primary cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02866006


Contacts
Layout table for location contacts
Contact: Wu Hyun Kim, DVM +82-2-3285-7861 whkim@cellid.co.kr
Contact: T G Oh, PH.D +82-2-3285-7861 whkim@cellid.co.kr

Locations
Layout table for location information
Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of
Contact: S A Park    +82-3410-6793      
Principal Investigator: C H Choi, PH.D         
Sponsors and Collaborators
Cellid Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: C Y Kang, PH.D Seoul National University

Layout table for additonal information
Responsible Party: Cellid Co., Ltd.
ClinicalTrials.gov Identifier: NCT02866006     History of Changes
Other Study ID Numbers: BVAC-C-P1
First Posted: August 15, 2016    Key Record Dates
Last Update Posted: July 18, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Cellid Co., Ltd.:
HPV
Type 16, 18
E6E7
Immune therapeutic vaccine

Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female